Novo Nordisk A/S Common Stock (NVO)

New products are already generating growth.

These biotech companies have catalysts ahead.

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

Ozempic's rival is generating blockbuster revenue and gaining market share.

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion market capitalization. This monumental achievement, finalized in early February 2026, marks a paradigm shift in how investors value

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Viking should have plenty of news to share with investors this year.

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Growth, value, or both?

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Both companies are betting on interest in weight loss pills.

Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.

As of February 11, 2026, the global economy is navigating the aftershocks of a geopolitical standoff that nearly dismantled the post-war trade order. The "Greenland Tariff Escalation," a high-stakes diplomatic confrontation sparked by the United States’ aggressive pursuit of the world’s largest island, has shifted from an imminent trade

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

This stock has been known to soar after good news.

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.